New Progestogens: A Review of Clinical Data

  • John A. Collins
Part of the Clinical Perspectives in Obstetrics and Gynecology book series (CPOG)


The past 5 years have witnessed important simultaneous developments in the understanding of the role of progesterone in the prevention and treatment of menopausal disorders, and in the evolution of a group of progestogens that may have fewer undesirable effects when used in postmenopausal women. The pharmacology and clinical applications of oral contraceptives based on the new progestins have been the subject of many publications, although applications among postmenopausal women have been reported less frequently. Each of these new progestins is related to the levonorgestrel (LNG) molecule, which differs by one methyl grouping from norethindrone (NET). The new compounds are desogestrel (DSG), gesto-dene (GSD), and norgestimate (NGM). The structural distinctions among this group of progestational steroids are relatively small, but these small differences allow for the possibility of distinguishable pharmacologic and clinical effects. Receptor and metabolic studies suggest that these different effects may favor the use of the new progestins. Clinical experience also suggests that efficacy and adverse affects (at least in relation to oral contraception) are similar in formulations based on the new progestogens, compared with compounds now in wide use.


Oral Contraceptive Obstet Gynecol Cyproterone Acetate Minor Side Effect Acta Obstet Gynecol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hemminki E, Kennedy DL, Baum C, McKin-lay SM. Prescribing of noncontraceptive estrogens and progestins in the United States, 1974–86. Am J Public Health. 1988; 78: 1478–1481.CrossRefGoogle Scholar
  2. 2.
    Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Br Med J, 1989; 298: 147–151.CrossRefGoogle Scholar
  3. 3.
    Utian WH. Consensus statement on progestin use in postmenopausal women. Maturitas. 1988; 11: 175–177.CrossRefGoogle Scholar
  4. 4.
    Knopp RH. The effects of postmenopausal estrogen therapy on the incidence of arteriosclerotic vascular disease. Obstet Gynecol. 1988; 72: 23S - 30S.PubMedGoogle Scholar
  5. 5.
    Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med. 1991; 325 (ll): 756–762.PubMedCrossRefGoogle Scholar
  6. 6.
    Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991; 151: 75–78.PubMedCrossRefGoogle Scholar
  7. 7.
    Collins JA. A review of clinical data on the new progestogens. J Soc Obstet Gynecol Can. 1991; 13: 40–50.Google Scholar
  8. 8.
    Ball MJ, Ashwell E, Jackson M, Gillmer MDG. Comparison of two triphasic contraceptives with different progestogens: effects on metabolism and coagulation proteins. Contraception. 1990; 41: 363–376.PubMedCrossRefGoogle Scholar
  9. 9.
    Petersen KR, Skouby SO, Pedersen RG. Deso-gestrel and gestodene in oral contraceptives: 12 months’ assessment of carbohydrate and lipoprotein metabolism. Obstet Gynecol. 1991; 78: 666–671.PubMedGoogle Scholar
  10. 10.
    Petersen KR, Skouby SO, Dreisler A, Kuhl C, Svenstrup B. Comparative trial of the effects on glucose tolerance and lipoprotein metabolism of two oral contraceptives containing gestoden and desogestrel. Acta Obstet Gynecol Scand. 1988; 67: 37–41.CrossRefGoogle Scholar
  11. 11.
    Falsetti L, Schivardi MR, Prandini BD. A new low-dose estrogen oral contraceptive combination: effect on endocrine parameters and lipid status. Contraception. 1987; 36: 489–497.PubMedCrossRefGoogle Scholar
  12. 12.
    Harvengt C, Desager JP, Gaspard U, Lepot M. Changes in lipoprotein composition in women receiving two low-dose oral contraceptives containing ethinylestradiol and gonane progestins. Contraception. 1988; 37: 565–575.PubMedCrossRefGoogle Scholar
  13. 13.
    Haarbo J, Christiansen C. Treatment-induced cyclic variations in serum lipids, lipoproteins, and apolipoproteins after 2 years of combined hormone replacement therapy: exaggerated cyclic variations in smokers. Obstet Gynecol. 1992; 80: 639–644.PubMedGoogle Scholar
  14. 14.
    Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles’, or vertebral fracture and cornonary heart disease among white postmenopausal women. Arch Intern Med. 1989; 149: 2445–2448.PubMedCrossRefGoogle Scholar
  15. 15.
    Naessen T, Persson I, Adami HO, Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk of first hip fracture: a prospective, population-based cohort study. Ann Intern Med. 1990; 113: 95–103.PubMedGoogle Scholar
  16. 16.
    Aloia JF. Role of calcitriol in the treatment of postmenopausal osteoporosis. Metabolism. 1990; 39: 35–38.PubMedCrossRefGoogle Scholar
  17. 17.
    Riggs BL, Hodgson SF, O’Fallon M, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990; 322: 802–809.PubMedCrossRefGoogle Scholar
  18. 18.
    Abdalla HI, McKay Hart D, Lindsay R, Leg-gate I, Hooke A: Prevention of bone mineral loss in postmenopausal women by norethi-sterone. Obstet Gynecol. 1985; 66: 789–792.PubMedGoogle Scholar
  19. 19.
    Prior JC. Progesterone as a bone-tropic hormone. Endocr Rev. 1990; 11: 386–398.PubMedCrossRefGoogle Scholar
  20. 20.
    Chapdelaine A, Desmarais J-L, Derman RJ. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil. 1989; 34: 347–352.PubMedGoogle Scholar
  21. 21.
    Refn H, Kjaer A, Lebech A-M, Borggaard B, Schierup L, Bremmelgaard A. Metabolic changes during treatment with two different progestogens. Am J Obstet Gynecol. 1990; 163: 374–377.PubMedGoogle Scholar
  22. 22.
    Vandervang N, Kloosterboer HJ, Haspels AA. Effects of seven low dose combined oral contraceptives on high density lipoprotein sub-fractions. Br J Obstet Gynecol. 1987; 94: 559–567.CrossRefGoogle Scholar
  23. 23.
    Jespersen J, Petersen KR, Skouby SO. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am J Obstet Gynecol. 1990; 163: 396–403.PubMedGoogle Scholar
  24. 24.
    Abbate R, Pinto S, Rostagno C, Bruni V, Rosati D, Mariani G. Effects of longer-term gestodene-containing oral contraceptive administration on hemostasis. Am J Obstet Gynecol. 1990; 163: 424–430.PubMedGoogle Scholar
  25. 25.
    Becker H. Supportive European data on a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand Suppl. 1990; 152: 33–39.PubMedCrossRefGoogle Scholar
  26. 26.
    Daly L, Bonnar J. Comparative studies of 30 fig ethinyl estradiol combined with gesto-dene and desogestrel on blood coagulation, fibrinolysis, and platelets. Am J Obstet Gynecol. 1990; 163: 430–437.PubMedGoogle Scholar
  27. 27.
    Fioretti P, Fruzzetti F, Nazalesi R, et al. Clinical and metabolic effects of a pill containing 30 meg ethinylestradiol plus 75 meg gestodene. Contraception. 1989; 40: 649–663.PubMedCrossRefGoogle Scholar
  28. 28.
    Kjaer A, Lebech A-M, Borggaard B, et al. Lipid metabolism and coagulation of two contraceptives: correlation to serum concentrations of levonorgestrel and gestodene. Contraception. 1989; 40: 665–673.PubMedCrossRefGoogle Scholar
  29. 29.
    Kloosterboer HJ, van Wayjen RGA, van den Ende A. Effects of three low-dose contraceptive combinations on sex hormone binding globulin, corticosteroid binding globulin and antithrombin II activity in healthy women: two monophasic desogestrel combinations (containing 0.020 or 0.030 mg ethinylestradiol) and one triphasic levonorgestrel combination. Acta Obstet Gynecol Scand Suppl. 1987; 144: 41–44.CrossRefGoogle Scholar
  30. 30.
    Omsjo IH, Oian P, Maltau JM, Osterud B. Effects of two triphasic oral contraceptives containing ethinylestradiol plus levonorgestrel or gestodene on blood coagulation andfibrinolysis. Acta Obstet Gynecol Scand. 1989; 68: 27–30.PubMedCrossRefGoogle Scholar
  31. 31.
    Gevers Leuven JA, Dersjant-Roorda MC, Heimerhorst FM, de Boer R, Meymeyer- Leloux A, Havekes L. Estrogenic effect of gestodene-or desogestrel-containing oral contraceptives on lipoprotein metabolism. Am J Obstet Gynecol. 1990; 163: 358.Google Scholar
  32. 32.
    Dusterberg B, Brill K. Clinical acceptability of monophasic gestodene. Am J Obstet Gynecol. 1990; 163: 1398–1404.PubMedGoogle Scholar
  33. 33.
    Allen HH. Clinical assessment of a low-dose oestrogen, low-dose progestogen combined oral contraceptive. Curr Med Res Opinion. 1974; 2: 101–108.CrossRefGoogle Scholar
  34. 33.
    Corson SL. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand Suppl. 1990; 152: 25–31.PubMedCrossRefGoogle Scholar
  35. 34.
    Droegemueller W, Rao Katta L, Bright TG, Bowers WA. Triphasic randomized clinical trial: comparative frequency of intermenstrual bleeding. Am J Obstet Gynecol. 1989; 161: 1407–1411.PubMedGoogle Scholar
  36. 35.
    Loudon NB, Kirkman RJE, Dewsbury JA. A double-blind comparision of the efficacy and acceptabolity of Femodene and Microgynon- 30. Europ J Obstet Gynecol Reprod Biol. 1990; 34: 257–266.CrossRefGoogle Scholar
  37. 36.
    Rekers H. Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel. Acta Obstet Gynecol Scand. 1988; 67: 171–174.PubMedCrossRefGoogle Scholar
  38. 37.
    Schilling LH, Bolding OT, Chenault CB, et al. Evaluation of the clinical performance of three triphasic oral contraceptives: a multi-center, randomized comparative trial. Am J Obstet Gynecol. 1989; 160: 1264–1268.PubMedGoogle Scholar
  39. 38.
    Tuimala R, Saranen M, Alapiessa U. A clinical comparision in Finland of two oral contraceptives containing 0.150 mg desogestrel in combination with 0.020 mg or 0.030 mg ethinylestradiol. Acta Obstet Gynecol Scand Suppl. 1987; 144: 7–12.CrossRefGoogle Scholar
  40. 39.
    Vlietinck R. Personal communication, 1991.Google Scholar
  41. 40.
    Yabur JA, Alvarado M, Brito V. Clinical evaluation of a new combined oral contraceptive desogrestrel-ethinylestradiol. Advances in Contraception. 1989; 5: 57–70.PubMedCrossRefGoogle Scholar
  42. 41.
    Refn H, Kjaer A, Lebech A-M, Borggaard B, Schierup L. Clinical and hormonal effects of two contraceptives: correlation to serum concentrations of levonorgestrel and gestodene. Contraception. 1989; 41: 259–269.CrossRefGoogle Scholar
  43. 42.
    Erkkola R, Hirvonen E, Luikku J, Lumme R, Mannikko H, Aydinlik S. Ovulation inhibitors containing cyproterone acetate or deso-gestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand. 1990; 69: 61–65.PubMedCrossRefGoogle Scholar
  44. 43.
    Carlborg L. Cyproterone acetate versus levon-orgestrel combined with ethinyl estradiol in the treatment of acne. Acta Obstet Gynecol Sand Suppl. 1986; 134: 29–32.CrossRefGoogle Scholar
  45. 44.
    Miller JA, Wojnarowska FT, Dowd PM, et al. Anti-androgen treatment in women with acne: a controlled trial. Br J Derm. 1986; 114: 705–716.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1994

Authors and Affiliations

  • John A. Collins

There are no affiliations available

Personalised recommendations